Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × selinexor × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 15 Recurrence 7 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, T-Cell, Peripheral 3 Glioblastoma 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Sarcoma 2 Primary Myelofibrosis 2 Neoplasms 2 Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Carcinoma, Squamous Cell 2 Waldenstrom Macroglobulinemia 1 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Richter's Transformation 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Myeloproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Liposarcoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1

Interventions

Carboplatin 28 pembrolizumab 21 Paclitaxel 20 Cisplatin 20 Pemetrexed 17 Gemcitabine 10 durvalumab 9 Nivolumab 9 osimertinib 8 130-nm albumin-bound paclitaxel 8 Everolimus 7 Docetaxel 7 Sunitinib 6 Sorafenib 6 Fluorouracil 5 Cetuximab 5 Axitinib 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 reolysin 3 liposomal doxorubicin 3 lenvatinib 3 epothilone B 3 catumaxomab 3 brigatinib 3 Trastuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02213133 2023-01-26

STARRS

Karyopharm Therapeutics Inc

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡